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DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING 
May 8, 2020 
Executive Summary 
 
UNM drug repurposing. NM cases. Doctors Without Borders. SNAP benefits online. NM 7th highest 
unemployment. Virtual LemonAid tonight. New N98 masks. Healthcare supply chain challenge. EMS lack 
resources. Infection risk in healthcare workers. COVID-19 on medical education. Human disinfectant 
chambers. Evidence of seroconversion. Dangers of considering herd immunity. Wastewater-based 
surveillance. More youths infected. Reconstructing ship spread. Pharmacoepidemiologic analysis. 
Clinicopathologic characteristics. Cancer treatment impact. Reduced voluntary psychiatric admission in Italy. 
Operating room management. Humidifiers reduce transmission. Phone contact tracing ethics. Call for patient 
database. Immunity certification program. Guidelines on tracheostomy, IBD, nose bleeding, pituitary tumors, 
and hematopoietic stem cells transplantation, benefits of low-PEEP, and of molecular diagnostics. FDA 
authorizes at-home test. Cephid Xpert test. MRSA nasal swabs. NIH remdesivir+barictinib RCT. Corticosteroid 
caution. Arbidol active in vitro. ACE/ARB systematic review.  In silico phytochemical and virus protease 
candidates. Potential zinc benefit. 31 new clinical trials. Glycemic control benefit. Psychological effects meta-
analysis and survey. Disease course model. Liver injury. Environmental and health perspectives. Olfactory and 
gustatory dysfunction. Vitamin D. Disease map. 
 
All of our past briefings are maintained in a UNM library repository here. 
Our continuously curated practice guidelines in the context of COVID-19 can be found here. 
Our continuously curated therapeutic evidence is maintained here. 
You may submit content for future briefings here. 
NM Highlights 
 UNM Scientists studying ways to repurpose older drugs 
Scientists at the university of New Mexico are using machine learning to analyze the university’s DrugCentral database to 
identify drugs that could be repurposed as treatments for the COVID-19 infection. The drugs, many of which were developed 
decades ago for very different health conditions, could be a game-changer at a time when there are no vaccines or broadly 
effective drug treatments for the disease. 
 New Mexico reports 9 more COVID-19 deaths and 181 additional cases on May 8 
The total positive cases and total deaths in the state are 4,673 and 181, respectively. As of today (5/8), the state has 
performed 93,262 tests, there are 201 individuals currently hospitalized for COVID-19, and 1189 COVID-19 cases have 
recovered. New NMDOH portal featuring epidemiologic breakdown of cases. 
 Doctors Without Borders team comes to NM to aid tribes 
Doctors Without Borders, an international medical humanitarian organization, announced that a nine-person team of 
physicians, nurse-midwives, logisticians, and a health promoter is now working in New Mexico and the Navajo Nation, and is 
assessing how they can provide support to pueblos across the state. The NM DOH reports that 56% of COVID-19 cases in the 
state are Native American.  
   
 
   
 
 USDA allows New Mexicans to use SNAP benefits online 
The USDA approved New Mexico to let families on Supplemental Nutrition Assistance Program (SNAP) benefits buy food from 
online retailers, such as Walmart and Amazon, in response to the pandemic. Karmela Martinez, the NM Income Support 
Division Director, says she hopes to see the program continue in New Mexico after the pandemic ends.  
 NM is 7th highest in unemployment claims over the past week 
Since March 16th, 33.5 million Americans have lost their employment. Not all states have been impacted equally, with New 
Mexico having the 7th highest increase in unemployment claims over the past week. There were 16,801 unemployment 
claims the week of April 27th, 2020, a 2,324% increase from April 2019. NM is currently 26th highest in unemployment 
claims since the start of the COVID-19 pandemic. 
 Virtual LemonAid digital arts livestream tonight at 8pm to support NM COVID-19 relief 
Virtual LemonAid is a major multidisciplinary digital arts festival leveraging the creative talent of our region to raise critical 
funds to provide aid and support to those most in need in our community during the COVID-19 crisis. The broadcast will be 
available on: Youtube Live, Facebook Live, Instagram Live, Santa Fe Community Television - SFCTV- Channel 16 (Comcast). 
Economics, Workforce, Supply Chain, PPE Highlights 
 New multilayer nanofiber filter for simulated airborne COVID-19 
A goal of the study was to develop air filters (e.g. respirator, facemask, ventilator, medical breathing filter/system) with 90% 
capture of 100-nm airborne COVID-19 with pressure drop of less than 30 Pa (3.1 mm water). The 6-layer charged nanofiber 
filter was developed and qualified as an 'N98 respirator' (98% capture efficiency for 300-nm NaCl aerosols) but with pressure 
drop below conventional N95. The 6-layer charged PVDF nanofiber filter provides good personal protection against airborne 
COVID-19 virus and nano-aerosols from pollution based on the N98 standard and is 10X more breathable than N95 
respirator.  
 Healthcare supply chains: COVID-19 challenges and pressing actions 
Healthcare requires 5 categories of products: pharmaceuticals, personal protective equipment, medical devices, medical 
supplies, and blood. Each of these categories has a distinct supply chain, and the failure of any 1 of these chains can wreak 
havoc on the health care system. Authors suggest that urgent action must be taken to ensure that our supply chains support 
our health care providers at this critical time and in the future.  
 A survey on EMS resource capacity and competency 
An online survey was randomly distributed between April 1, 2020, and April 16, 2020 to various active Emergency Medical 
Services (EMS) paid personnel in all 50 U.S. states (n=192). An overwhelming number of EMS providers report having limited 
access to N95 respirators, receiving little or no benefits from COVID-19 related work, and report no institutional policy on 
social distancing practices despite CDC recommendations. For providers who do have access to N95 respirators, 31% report 
having to use the same mask for 1 week or longer. Approximately 1/3 of the surveyed participants were unsure of when a 
COVID-19 patient is infectious. The data suggests regular decontamination of EMS equipment after each patient contact is 
not a regular practice.  
 Epidemiology, PPE, and risk factors for infection in healthcare workers 
A living rapid review regarding SARS-CoV-1 and SARS-CoV-2 finds that healthcare workers generally experience a high 
incidence of infection although apparently less severe illness and mortality than non-healthcare workers. PPE use was 
generally associated with dose-dependent decreased risk. Although masks showed the most consistent association, risk 
reduction was observed for gloves, gowns, eye protection, handwashing, and training in infection control measures. It found 
evidence that N95 masks may be superior to surgical masks. Increased infection risk was observed with involvement in 
intubations, and direct contact with infected patients or their bodily secretions.  
 The impact of COVID-19 on medical education 
Cureus Editorial: The replacement of in-person with online classes, the cancellation of clerkships, and the loss of conference 
presentations present a challenge for medical students trying to distinguish themselves on residency applications. Small 
   
 
   
 
group learning, sharing best practices, and implementing webinar technology are ways to combat this.  
 SARS-CoV-2 human disinfection chambers: a critical analysis 
Rapid human disinfection chambers have emerged as an innovation for the pandemic. They have an entry point, an exit 
point, an enclosed chamber where the disinfection takes place, power supply, solvent supply, chemical chamber/mixer, air 
supply and compressor, as well as a spray mechanism. The paper examines the viricidal activity of various agents, along with 
safety/toxicity considerations for repeated human exposure. Researchers concluded that though limited exposure to a 
chemical may not show harm, that does not mean the chemical or compound is safe. 
Epidemiology Highlights  
 Most people carry antibodies after recovering 
MedRxiv preprint: Seroconversion and PCR-positivity was investigated in 1343 convalescent serum donors in New York City. 
All but three confirmed SARS-CoV-2 patients seroconverted to the SARS-CoV-2 spike, while only 37.4% of suspected SARS-
CoV-2 patients seroconverted. Nasopharyngeal SARS-CoV-2 RNA was detected up to 28 days from symptom resolution. The 
vast majority of confirmed COVID19 patients seroconvert, potentially providing immunity to reinfection. They also report that 
in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks post 
symptom resolution, but it is unclear if this signal represents infectious virus. Story also covered in New York Times. 
 Herd Immunity against COVID-19: A dangerous misconception 
Two infectious disease epidemiologists clearly state that herd immunity against COVID-19 will not be achieved at a 
population level in 2020, barring a public health catastrophe. In New York City, initial studies suggest that perhaps 15-21% of 
people have been exposed so far, with more than 17,500 dead. "To reach herd immunity for COVID-19, likely 70% or more of 
the population would need to be immune. Without a vaccine, over 200 million Americans would have to get infected before 
we reach this threshold." This will not occur before mid-2021; at the current daily death rates, up to half a million Americans 
could die of COVID19 by that time. 
 Computational analysis of COVID-19 surveillance by wastewater-based epidemiology 
Scientists are turning now to wastewater-based epidemiology (WBE) as a tool for assessing and managing the pandemic. The 
authors employed computational analysis and modeling to examine the feasibility, economy, opportunities and challenges of 
enumerating active coronavirus infections locally and globally using WBE. Depending on local conditions, detection in 
community wastewater of one symptomatic/asymptomatic infected case per 100 to 2,000,000 non-infected people is 
theoretically feasible. WBE surveillance of populations is shown to be orders of magnitude cheaper and faster than clinical 
screening yet cannot fully replace it. Cost savings worldwide for one-time national surveillance campaigns are estimated to 
be in the million to billion US dollar range (US$), depending on a nation's population size and number of testing rounds 
conducted. For resource poor regions and nations, WBE may represent the only viable means of effective surveillance. 
Important limitations of WBE rest with its inability to identify individuals and to pinpoint their specific locations.  
 Rising proportion of youth among COVID-19 cases following the physical distancing 
Using data on COVID-19 cases in Germany from the Robert Koch Institute, the authors found a relative increase with time in 
the prevalence in 15 to 34-year-olds (particularly 20-24-year-olds) compared with 35-49- and 10-14-year-olds (we excluded 
older and younger ages because of different healthcare seeking behavior). This suggests an elevated role for that age group 
in propagating the epidemic following the introduction of physical distancing measures.  
 Computational methods reconstructing COVID-19 spread on the "Diamond Princess" ship 
A contact network was used to reconstruct unprotected, protected contact, and airborne spread to simulate the two-stages 
outbreak of COVID-19 on the "Diamond Princess" cruise ship. During the early epidemic with intensive social contacts, the 
results reveal that the average transmissibility (t) was 0.026 and the basic reproductive number R 0 was 6.94, triple that in 
the WHO report, indicating that all people would be infected in one month. The t and R0 decreased to 0.0007 and 0.2 when 
quarantine was implemented. The reconstruction suggests that diluting the airborne virus concentration in closed settings is 
useful in addition to isolation, and high-risk susceptible should follow rigorous prevention measures in case exposed. 
 Considerations for pharmacoepidemiological analyses in COVID-19 
   
 
   
 
In this paper, endorsed by the International Society for Pharmacoepidemiology, methodological considerations are provided 
for the conduct of pharmacoepidemiologic studies in relation to the pandemic across eight domains: (1) timeliness of 
evidence, including the need to prioritize some questions over others in the acute phase of the pandemic; (2) the need to 
align observational and interventional research on efficacy; (3) the specific challenges related to 'real-time epidemiology' 
during an ongoing pandemic; (4) what design to use to answer a specific question; (5) considerations on the definition of 
exposures; (6) what covariates to collect; (7) considerations on the definition of outcomes; and (8) the need for transparent 
reporting. 
 Characteristics of 8697 patients with COVID-19 in China: a meta-analysis 
Meta-analysis showed that a higher proportion of infected patients were male (53.3%), and the two major symptoms 
observed were fever (78.4%) and cough (58.3%). Other common symptoms included fatigue (34%), myalgia (21.9%), 
expectoration (23.7%), anorexia (22.9%), chest tightness (22.9%) and dyspnea (20.6%). Only 5.4% of the patients were 
asymptomatic. Most patients showed normal leucocyte counts (64.7%) and elevated C reactive protein levels (65.9%). 
Lymphopenia was observed in about 47.6% of the infected patients, along with abnormal levels of myocardial enzymes 
(49.4%) and liver function (26.4%). Other findings included leucopenia (23.5%), elevated D-dimer (20.4%), elevated 
erythrocyte sedimentation rate (20.4%), leukocytosis (9.9%), elevated procalcitonin (16.7%) and abnormal renal function 
(10.9%).  
 Impact of COVID-19 on cancer patients in NYC center 
The New York Proton Center (NYPC) is a high-volume free-standing multi-institutional proton center. The purpose of this 
report is to describe the institutional patient experience and quantify the impact of treatment delays and interruptions over 
the first month of the COVID-19 outbreak. Despite the early implementation of measures and policies, NYPC still had 11% of 
patients affected, including 3% confirmed positive for COVID-19 within the first month and one patient death. All the delays 
at NYPC occurred in the second half of the month, suggesting other cities should expect and prepare for an acceleration of 
patient events near their projected regional pandemic peak.  
 Reduced voluntary psychiatric admissions in Italy after pandemic start 
In the 40-day period (February 21st-March 31st 2020) after the start of the COVID-19 epidemic in Italy, compared to a similar 
40-day period prior to 21 February, and compared to two 40-day periods of 2019, there has been a marked reduction in 
psychiatric admission rates. The reduction was explained by voluntary admissions, while there was not a noticeable reduction 
for involuntary admissions. The reduction was visible for all diagnostic groups, except for a group of 'Other' diagnoses, which 
includes anxiety disorders, neurocognitive disorders, etc.  
Healthcare Policy Recommendations 
 Strategies for daily ambulatory operating room management after acute phase of COVID-19 
The article suggests dedicating most operating rooms to procedures that are not airway aerosol producing and can be 
performed without general anesthesia. Other suggestions are to increase throughput by performing nerve blocks before 
patients enter the operating rooms, bypass the phase I post-anesthesia care unit whenever possible by appropriate choices 
of anesthetic approach and drugs, and plan long-duration workdays (e.g., 12-h). The authors recommend using statistical 
methods to plan for the resulting long turnover times. Whenever possible, have the anesthesia and nursing teams stagger 
cases in more than one room so that they are doing one surgical case while the other room is being cleaned.  
 Humidifiers to reduce viral transmission 
According to recent studies, COVID-19 transmission is more efficient in dry, cold climates. Further, when the respiratory 
mucosal barrier is dehydrated, it loses structural integrity, promoting viral transmission. The authors suggest aggressive re-
humidification of dry air in all public and private heated spaces, especially in areas containing patients on ventilators.  
 Ethical implications of using phone apps for contact tracing 
Contact tracing is an essential practice to combat the spread of infection. COVID-19 is especially complicated, as a high 
proportion of infection is spread pre-symptomatically. To combat this, phone apps offer a more instantaneous means to 
perform contact tracing. However, using a phone app for 'intelligent physical distancing' raises many ethical concerns, such 
   
 
   
 
as individuals unable to maintain data security and privacy.  
 Researchers call for COVID-19 patient health record database 
Lancet: Currently, there is no pooled, publicly-available dataset on COVID-19 patients. The authors make the argument that 
access to this data would greatly benefit researchers and could expedite global efforts to combat the virus. It is noted that 
the absence of this database is not due to absence of technology or precedent, as there is a database established in 1996 
that provides researchers with deidentified health record data on intensive care patients.  
 Consideration of a COVID-19 immunity certification program 
JAMA Viewpoint examines the U.S. government’s consideration of an immunity certification program based on past COVID-
19 infection or positive antibody testing. Individuals with such certification could be allowed certain work and social 
freedoms, such as attending events with large groups. The article highlights temporary inequities in civil liberties that could 
come with such a program, advocates focusing on healthcare workers when supplies are limited, and ensuring equal access 
to testing thereafter. As COVID-19 is not yet vaccine-preventable and there is not yet universal availability of antibody 
testing, developing such a program would require more time and consideration. 
Practice Guidelines 
 Guidelines for tracheostomy: American Association for the Surgery of Trauma 
The guidelines from the Critical Care and Acute Care Surgery Committees of the American Association for the Surgery of 
Trauma are provided on tracheostomy in known or suspected Covid-19 patients.  
 Guidelines on management of IBD patients during the COVID-19 pandemic 
Here, the World Endoscopy Organisation (WEO) is providing practical advice for the management of inflammatory bowel 
disease (IBD) patients during the pandemic covering the diagnostic and therapeutic aspects.  
 Recommendations for nose bleeding management during the COVID-19 pandemic 
Recommendations include: thorough history taking, wearing PPE, performing invasive treatments in operating room or well 
demarcated areas, and postponing sphenopalatine artery ligation (for posterior epistaxis) until COVID-19 testing has been 
performed. The use of local anesthetic atomized sprays should be avoided, and soaked pledgets should be preferred. A 
suction system should be used during the procedure within a closed system with a viral filter. 
 Management of pituitary tumors during COVID-19 
Recommendations are provided by a group of international researchers. Face to face visits for patients with pituitary tumors 
could be postponed in most cases for 3-6 months without compromising optimal care. Endocrine help-line run by 
endocrinologists and endocrine nurses should be available 24/7 aiming to offer immediate support to patients with urgent 
problems/queries, to reduce anxiety and to reduce workload of primary care clinicians. Dissemination of websites of patient 
support groups is strongly recommended. 
 International guidelines for hematopoietic stem cell transplantation 
The guidelines were issued by the European Society for Blood and Marrow Transplantation (EBMT) and American Society for 
Transplantation and Cellular Therapy (ASTCT). They include a negative COVID-19 PCR test prior to transplant as well as 
completing 14 days of isolation before starting transplant conditioning. Donors who test positive for COVID-19, who are 
symptomatic, or who have traveled to high risk areas should defer to donate unless the case is urgent and there are no 
alternative donors. As of March 20,2020, 15 cases of COVID-19 cases in post-hematopoietic stem cell transplantation setting 
(15 allogenic and 3 autologous) have been reported from Europe with one death.  
 Care map and low PEEP reduce ventilation days, ICU admission, mortality and LOS 
In a retrospective analysis of clinical data on patients with COVID-19 pneumonia and ARSD admitted to ICU an increased 
survival was observed in patients with low positive end-expiratory pressure (PEEP) compared to other groups. A possible 
explanation could be that the relative low-pressure ventilation avoids transforming an initial alveolitis into an ARDS-iatrogenic 
framework, in which the local ongoing inflammation is rather damaged than helped by high PEEP (generating a Ventilation-
Induced-Lung Injury - VILI) in a context that is the “not-classic” ARDS. The authors also recommend their multimodal program 
   
 
   
 
(“care map”) which implements Early Warning Score (EWS) monitoring for intermediate care patients, in order to perform a 
strict selection of ICU admission and employ mechanical ventilation as little as necessary. This program allowed to reduce the 
number of ICU admissions, the number of ventilation days and mortality. 
 Molecular testing for acute respiratory tract infections: recommendations 
The Diagnostics Committee of the Infectious Diseases Society of America (IDSA) conducted a literature review. Compared to 
classical culture-and antigen-based methods, molecular tests have high sensitivity and there is potential for a clinically 
meaningful turn-around-time to actionable results. Respiratory NAAT is most useful in the setting of intermediate pre-test 
probability and intermediate disease severity. This is a situation where a negative test may permit withholding of initial 
empiric coverage of a potential pathogen, whereas a positive test can allow therapy to be focused against a particular 
pathogen, thus increasing therapeutic efficacy, decreasing avoidable drug-toxicity, and potentially reducing unnecessary 
additional testing.  
Testing 
 FDA authorizes first at-home saliva test 
The RUCDR Infinite Biologics test will cost $150 and needs to be fully supervised by a practitioner via telemedicine to ensure 
proper sample collection. Test analysis will be performed at Rutgers Clinical Genomics Laboratory and results will be available 
within 48-72 hours.  
 New Cepheid Xpert Xpress automated molecular test shown to be rapid, sensitive, and accurate 
The limit of detection of the 45-minute Xpert test was 0.01 plaque forming units (PFU)/mL. Other hCoVs were not detected 
by the Xpert test. SARS-CoV was detected by a broad-range target (E) and was distinguished from SARS-CoV-2 (SARS-CoV-2-
specific N2 target). Compared to nucleic acid amplification tests (NAAT), the positive agreement of the Xpert test was 
219/220 (99.5%) and the negative agreement was 250/261 (95.8%). A third tiebreaker NAAT resolved all but three of the 
discordant results in favor the Xpert test. 
 MRSA nasal swabs can be used to detect SARS-CoV-2 
MRSA nasal swabs showed a high concordance with respiratory viral swabs. In situations where respiratory viral swabs are in 
scarce supply, health care workers can use MRSA nasal swabs with similar virus detection accuracy.  
Drugs, Vaccines, Therapies, Clinical Trials  
 NIH announces trial combining antiviral remdesivir and antiinflammatory drug baricitinib 
The NIAID-sponsored trial is expected to open at approximately 100 U.S. and international sites and enroll more than 1000 
participants. Baricitinib, taken orally, inhibits cytokine signaling in the body that plays a role in causing inflammatory 
responses. The putative benefit of baricitinib for COVID-19 has been described in a case series of critically ill patients who 
recovered. The combination of remdesivir and baricitinib has not been evaluated in a large, randomized controlled treatment 
trial. One arrm will receive baricitinib tablets orally and intravenous (IV) remdesivir, and the other will receive placebo tablets 
orally and IV remdesivir in this double-blind study. The primary outcome is time to recovery, with secondary outcomes 
examining severity and mortality.  
 Corticosteroids and SARS-CoV-2/SARS-CoV/MERS-CoV outcomes: a meta-analysis advises caution 
Corticosteroid use was associated with delayed virus clearing with a mean difference (MD) = 3.78 days (95% confidence 
Interval [CI] = 1.16, 6.41 days; I(2) = 0%). There was no significant reduction in deaths with relative Risk Ratio (RR) = 1.07 (90% 
CI = 0.81; 1.42; I(2) = 80%). Hospitalization duration was prolonged and use of mechanical ventilation increased.  
 The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro 
The authors evaluated six currently available and licensed anti-influenza drugs against SARS-CoV-2 in vitro: arbidol, baloxavir, 
laninamivir, oseltamivir, peramivir, and zanamivir. Among the six drugs, only arbidol efficiently inhibited SARS-CoV-2 
infection. Functionally, it appears to block virus entry by impeding viral attachment and release from the endolysosomes. 
Although the selectivity index (SI) of arbidol is relatively low (SI=7.73), as a repurposed drug, its pharmacokinetics profile such 
   
 
   
 
as maximal concentration (Cmax) is more important for predicting efficacy.  
 ACEi and ARBs not associated with adverse events or death 
Systematic review and meta-analysis did not find evidence of an increase in critical events and mortality in hospitalized 
patients given these medications for hypertension.  
 In silico screening of natural phytochemical compounds against COVID-19 
The authors created a phytochemical library of 318 phytochemicals from 11 plants which have been reported as having 
antiviral, antibacterial or antifungal activity. It was subjected to virtual screening against molecular targets; Main protease 
(Mpro) and Angiotensin-Converting Enzyme 2 (ACE2). The top 10 compounds were selected from each target. 
 Targeting virus protease: drug candidates found through virtual screening of the ChEMBL database 
The main protease M(pro) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M(pro) homodimer structure 
suitable for docking simulations was prepared using a crystal structure. Structure-based virtual screenings of 1,485,144 
compounds predicted 64 potential drugs (11 approved, 14 clinical, and 39 preclinical drugs) to show high binding affinity with 
M(pro). Additional docking simulations for predicted compounds with high binding affinity with M(pro) suggested that 28 
bioactive compounds may have potential as effective anti-SARS-CoV-2 drug candidates.  
 Potential zinc benefit in non-randomized retrospective hydroxychloroquine+azithromycin study 
MedRxiv preprint of retrospective observational study, not peer-reviewed: Patients were categorized based on their 
exposure to hydroxychloroquine+azithromycin  alone (n=521) or with zinc sulfate (n=411) as treatment in addition to 
standard supportive care. The two groups did not differ with respect to age, race, sex, tobacco use or past medical history. 
After adjusting for zinc therapy timing, the authors found that addition of zinc sulfate to hydroxychloroquine and 
azithromycin is associated with an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) and significant 
reduction in mortality or transfer to hospice (OR 0.449, 95% CI 0.271-0.744). 
  31 New COVID-19 Trials registered today at clinicaltrials.gov 
Treatment trials: olokizumab, RPH-104, NT-17, azoximer bromide, acalabrutinib, clazakizumab, atorvastatin, melphalan, 
Chinese herbal medicine, sirukumab, ciclesonide, low-dose radiotherapy, hydroxychloroquine, ritonavir/lopinavir, 
tocilizumab, azithromycin, corticosteroid, low molecular weight heparin, oxygen, convalescent plasma, BNT162a1, 
BNT162b1, BNT162b2, BNT162c2. At time of writing, a total of 1271 were active,  63 completed, and 3 posted results. 
Other Science 
 Improved glycemic control associated with better outcomes type 2 diabetics 
This retrospective, multi-centered study (n=7,337) of COVID-19 patients in Hubei, China found that subjects with Type 2 
diabetes (n=952) required more medical interventions and had a significantly higher mortality (7.8% vs 2.7%; adjusted HR, 
1.49) and multiple organ injury than the non-diabetic individuals. Well-controlled blood glucose was associated with 
markedly lower mortality than individuals with poorly controlled blood glucose during hospitalization.  
 Psychological effects of virus outbreaks on healthcare workers: meta-analysis 
Compared with lower risk controls, staff in contact with affected patients had greater levels of both acute or post-traumatic 
stress (odds ratio 1.71, 95% CI 1.28 to 2.29) and psychological distress (1.74, 1.50 to 2.03), with similar results for continuous 
outcomes. Risk factors for psychological distress included being younger, being more junior, being the parents of dependent 
children, or having an infected family member. Clear communication, access to adequate personal protection, adequate rest, 
and both practical and psychological support were associated with reduced morbidity.  
 Italian survey of increased psychological distress during the COVID-19 pandemic 
An online survey using logistic regression models examined the associations between sociodemographic variables; 
personality traits; depression, anxiety, and stress. Female gender, negative affect, and detachment were associated with 
higher levels of depression, anxiety, and stress. Having an acquaintance infected increased levels of both depression and 
stress, whereas a history of stressful situations and medical problems was associated with higher levels of depression and 
anxiety. Finally, family members infected and young person and work outside their domicile presented higher levels of 
   
 
   
 
anxiety and stress, respectively.  
 Computational prediction for disease progression in mild COVID-19 
The risk factors for requiring of oxygen support in mild COVID-19 were explored using multivariate logistic regression. 
Nomogram as visualization of the models was developed using R software (N=344 patients). When the laboratory data were 
not included in multivariate analysis, diabetes, coronary heart disease, T >=38.5 and sputum were independent risk factors of 
progressive COVID-19 (Model 1). When the blood routine test was included the CHD, T >=38.5 and NLR were found to be 
independent predictors (Model 2). The AUROC of model 2 was larger than model 1 (0.872 vs. 0.849, P =0.023). The negative 
predictive value of both models was greater than 96%, indicating they could serve as simple tools for ruling out the possibility 
of disease progression.  
 Liver injury increases with disease severity: Systematic review and meta-analysis 
MedRxiv preprint: Data from studies (n=57) on Chinese patients (n=9889) showed that among the patients with early 
infection, the incidence of liver injury events was 24.7% (95% CI, 23.4%-26.4%). Liver injury in severe patients was more 
common than that in non-severe patients, with a risk ratio of 2.07 (95% CI, 1.77 to 2.43). Quantitative analysis showed that 
the severe the coronavirus infection, the higher the level of aspartate aminotransferase, alanine aminotransferase, total 
bilirubin, alkaline phosphatase, and gamma-glutamyl transpeptidase and the lower the level of albumin. 
 A summary of environmental and health perspectives of COVID-19 
This Opinion Paper provides a summary of recent findings and solutions for a better understanding of the environmental and 
health problems associated with COVID-19. The list of topics covered is: meteorology and air quality factors with correlation 
number of infections, sewage waters as a way to reveal the scale of COVID-19 outbreak, current hospital disinfection 
procedures and new eco-friendly technologies and list of drug therapies recommend waiting for the desired vaccine to come.  
 Olfactory and Gustatory Dysfunction common in COVID-19 Patients: meta-analysis 
A meta-analysis of 10 studies (n=1627) showed a 52.73% (95% CI 26.64%-75.23%) prevalence of olfactory dysfunction among 
patients with COVID-19. An analysis of 9 studies (n=1390) showed a 43.93% (95% CI 20.46%-68.95%) prevalence of gustatory 
dysfunction. This indicates that olfactory and gustatory dysfunction are common symptoms in COVID-19 patients and may 
represent early symptoms in the clinical course of infection.  
 Evidence supports a causal model for Vitamin D in COVID-19 outcomes 
An analysis of global data for COVID-19 deaths and recoveries shows that outbreak severity displays a striking latitude 
relationship with a northern hemisphere bias. Using Causal Inference, the authors highlight known pathways that involve 
Vitamin D and show how these protect against viral infection and ameliorate symptoms in COVID-19 and other respiratory 
diseases.  
 COVID-19 Disease Map, a computational repository of virus-host interaction mechanisms 
The COVID-19 Disease Map is announced (https://doi.org/10.17881/covid19-disease-map), an effort to build a 
comprehensive, standardized knowledge repository of SARS-CoV-2 virus-host interaction mechanisms, guided by input from 
domain experts and based on published work.  
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